

*Entities using this material are responsible for and should pay close attention to the accuracy of the information about their company. This template is provided to any appropriately requesting entity, regardless of the manner in which they cover, recommend, or participate in the ordering of the Oncotype DX Breast Recurrence Score® test.*

*You may adapt the provided content to suit the needs of your organization, including the removal of the Exact Sciences logo and copyright information.*

Following the recent publication of initial study results in The New England Journal of Medicine, updated data were presented in an oral session at SABCS® by Dr. Kevin Kalinsky, study lead investigator of the RxPONDER trial. In an analysis with longer follow-up (median 6.1 years) from the prior years' reporting, the investigators reported that postmenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 do not benefit from adjuvant chemotherapy.<sup>1</sup> In addition, a new analysis of distant recurrence-free interval (defined as time to distant recurrence or death from breast cancer) showed that premenopausal women with Recurrence Score results 0-13 received a modest 2.3% absolute benefit at five years. For those with Recurrence Score results 14-25 the benefit was 2.8%.

Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2-negative early breast cancer have a tumor that has spread to their lymph nodes.<sup>2</sup> A large majority of these patients currently receive chemotherapy<sup>2</sup> even though approximately 85% of them have Recurrence Score results 0 to 25.<sup>3</sup> In addition, approximately two out of three early-stage breast cancer patients are postmenopausal.<sup>4</sup>

The RxPONDER trial, coupled with the landmark TAILORx<sup>5</sup> study, have shown that most newly diagnosed women with HR+, HER2- breast cancer can be safely spared from chemotherapy. Additionally, RxPONDER data showed that a node-positive breast cancer diagnosis does not automatically mean chemotherapy.<sup>1</sup>

1 Kalinsky, K. et al., *New Engl J Med*. 2021.

2 Zhang et al., *Breast Can Res Treat*. 2020.

3 Bello et al., *Ann Surg Oncol*. 2018.

4 Heer E. et al., *The Lancet*. 2020

5 Sparano et al. *N Engl J Med*. 2018.

*Oncotype DX Breast Cancer Recurrence Score, and Recurrence Score are registered trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation.*

*© 2021 Genomic Health, Inc. All rights reserved*